ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
98.10
-0.86 (-0.87%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close98.96
Open98.21
Bid0.00 x 900
Ask129.89 x 800
Day's Range96.72 - 98.69
52 Week Range62.96 - 153.99
Volume588,716
Avg. Volume1,084,917
Market Cap9.861B
Beta3.26
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?
    Motley Fool7 days ago

    Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?

    Good news for Pfizer muddies the waters somewhat for Alnylam's outlook.

  • BioMarin Begins Mid Stage Study on Gene Therapy Candidate
    Zacks8 days ago

    BioMarin Begins Mid Stage Study on Gene Therapy Candidate

    BioMarin (BMRN) initiates a mid-stage study to evaluate its gene therapy candidate, valoctocogene roxaparvovec for treating in AAV5+ severe hemophilia A.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit15 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Thomson Reuters StreetEvents15 days ago

    Edited Transcript of ALNY earnings conference call or presentation 3-May-18 8:30pm GMT

    Q1 2018 Alnylam Pharmaceuticals Inc Earnings Call

  • Alnylam Looks Forward
    Motley Fool16 days ago

    Alnylam Looks Forward

    An uneventful earnings release as the company anticipates an approval of its hereditary TTR amyloidosis drug, patisiran.

  • Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss
    Zacks20 days ago

    Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss

    Alnylam (ALNY) incurs narrower-than-expected loss and missed revenue estimates in Q1. With several pipeline related events lined up and potential approval for patisiran, we expect investor focus to remain on the related updates.

  • Associated Press21 days ago

    Alnylam: 1Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.41. Losses, adjusted for stock option expense, came to $1.22 per share. The results did not meet Wall Street expectations. ...

  • Boston biotech entrepreneur Christoph Westphal launches new startup
    American City Business Journals22 days ago

    Boston biotech entrepreneur Christoph Westphal launches new startup

    Westphal has a long track record of co-founding successful drug developers, including Alnylam Pharmaceuticals and Momenta Pharmaceuticals.

  • Dicerna Pharmaceuticals Settles All Litigation with Alnylam
    Market Realist29 days ago

    Dicerna Pharmaceuticals Settles All Litigation with Alnylam

    On April 20, Dicerna Pharmaceuticals (DRNA) announced that it had resolved all litigation with Alnylam Pharmaceuticals (ALNY). The settlement allows Dicerna to advance all its key and planned pipeline programs while simultaneously maintaining a strong balance sheet. Under the terms of the agreement, Alnylam will dismiss all claims of trade secret misappropriation and other related claims brought in Massachusetts against Dicerna Pharmaceuticals.

  • Motley Foollast month

    Why Dicerna Rocketed Higher Today

    Investors are happy the biotech ended a lawsuit hanging over its head.

  • Dicerna to pay $27M to settle Alnylam trade secrets lawsuit
    American City Business Journalslast month

    Dicerna to pay $27M to settle Alnylam trade secrets lawsuit

    The Cambridge biotechs are both developing RNA interference drugs, which are designed to silence disease-causing genes.

  • Reuterslast month

    U.S. biotech companies Alnylam, Dicerna settle trade secrets case

    Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments. The settlement between the two biotech companies resolves a lawsuit that Alnylam filed against Dicerna in 2015. Under the agreement, Dicerna said it will pay Alnylam $2 million up-front plus 983,208 shares of its common stock.

  • Reuterslast month

    U.S. biotech companies Alnylam, Dicerna settle trade secrets case

    Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments. The settlement between the two biotech companies resolves a lawsuit that Alnylam filed against Dicerna in 2015. Under the agreement, Dicerna said it will pay Alnylam $2 million up-front plus 983,208 shares of its common stock.

  • Alnylam (ALNY) Reports Positive Data for RNAi Candidate
    Zackslast month

    Alnylam (ALNY) Reports Positive Data for RNAi Candidate

    Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ALNY totaled $105 million.

  • Jakafi Continues to Be Strong Growth Driver for Incyte in 2018
    Market Realistlast month

    Jakafi Continues to Be Strong Growth Driver for Incyte in 2018

    Incyte has projected Jakafi’s GAAP (generally accepted accounting principles) and non-GAAP revenues for full-year 2018 to fall in the range of $1.35 billion to $1.4 billion. This revenue performance could be driven by an anticipated rise in demand for the drug in existing rare blood cancer indications of myelofibrosis (or MF) and polycythemia vera (or PV) as well as from potential new indications such as graft versus host disease (or GVHD) and essential-thrombocythemia (or ET). Jakafi has been granted orphan drug designation in MF, PV, ET, GVHD, and acute lymphoblastic leukemia (ALL) indications.

  • Why CASI Pharmaceuticals Stock Rose Last Week
    Market Realistlast month

    Why CASI Pharmaceuticals Stock Rose Last Week

    On Monday, April 2, 2018, CASI Pharmaceuticals (CASI) stock opened at $4.20. It grew ~68% over the week to close at $7.01 on April 6. Its 52-week low was $0.91 on June 20, 2017.

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY

  • Forbeslast month

    A Sixth Sense For Biotech Has Made Joe Edelman A Hedge Fund Star

    Who's the world's best hedge fund manager? David Tepper? Stevie Cohen? Try Joe Edelman, a wannabe psychologist with a bead on biotech who has quietly built the best track record of the past two decades.

  • Benzinga2 months ago

    The Week Ahead In Biotech: PDUFA Dates, IPOs And More

    Here's a few must-watch biotech catalysts this week . Conferences Panamerican League of Associations for Rheumatology Congress – April 7-11 at Hotel Hilton, Buenos Aires, Argentina. The International Liver ...

  • See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY

  • How Worried Should Alnylam and Ionis Really Be About Pfizer's New Data?
    Motley Fool2 months ago

    How Worried Should Alnylam and Ionis Really Be About Pfizer's New Data?

    A battle for transthyretin amyloidosis patients is brewing.

  • Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?
    Market Realist2 months ago

    Why Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?

    On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53. On March 29, Regeneron stock closed at $344.36, which represented a ~7.2% rise from its share price in the week ended March 23, 2017. On March 21, 2018, Regeneron Pharmaceuticals announced a collaboration agreement with Alnylam Pharmaceuticals (ALNY) for the identification of RNA interference therapeutics for the treatment of chronic liver disease NASH (non-alcoholic steatohepatitis) and other related diseases.

  • Market Exclusive2 months ago

    Here’s What Just Happened With Zosano Pharma Corporation And Pfizer Inc

    Zosano Pharma Corporation (NASDAQ:ZSAN) was a real end of the week mover in the biotechnology sector last week, with the company sliding close to 45% on the news that it is set to conduct an underwritten public offering. The public offering will see Zosano issue 10 million shares at an average price of five dollars […] The post Here’s What Just Happened With Zosano Pharma Corporation And Pfizer Inc appeared first on Market Exclusive.

  • Analysts’ Recommendations for United Therapeutics in March 2018
    Market Realist2 months ago

    Analysts’ Recommendations for United Therapeutics in March 2018

    A Look into the Performance of United Therapeutics in 2017